Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background The antibiotic rifaximin is used to treat non-constipated irritable bowel syndrome (IBS). Methane production is associated with constipation and its severity in constipation-predominant IBS (C-IBS). A previous retrospective study suggested that rifaximin and neomycin was superior to neomycin alone in improving symptoms in methane-positive subjects.Aims To determine the effectiveness of neomycin alone or with rifaximin in improving symptoms in methane-positive C-IBS subjects.Methods A double-blind, randomized, placebo-controlled trial was performed from 2010 to 2013 at three tertiary care centers. Subjects aged 18-65 with C-IBS (Rome II criteria) and breath methane (>3 ppm) meeting the inclusion and exclusion criteria were recruited. Subjects completed a baseline symptom questionnaire rating the severity of abdominal and bowel symptoms on a visual analog scale and were randomized to receive neomycin and placebo or neomycin and rifaximin for 14 days. Symptom severity was assessed by weekly questionnaire for 2 weeks of therapy and 4 additional weeks of follow-up.Results Thirty-one subjects (16 neomycin and placebo, 15 neomycin and rifaximin) were included in the intention-to-treat analysis. Constipation severity was significantly lower in the neomycin and rifaximin group (28.6 ± 30.8) compared to neomycin alone (61.2 ± 24.1) (P = 0.0042), with greater improvement in constipation (P = 0.007), straining (P = 0.017) and bloating (P = 0.020), but not abdominal pain. In the neomycin and rifaximin group, subjects with methane <3 ppm after treatment reported significantly lower constipation severity (30.5 ± 21.8) than subjects with persistent methane (67.2 ± 32.1) (P = 0.020).Conclusions Rifaximin plus neomycin is superior to neomycin alone in improving multiple C-IBS symptoms. This effect is predicted by a reduction in breath methane.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst most antibiotics are not suitable for treating excessive methane production, a combination of rifaximin and neomycin have been effective in reducing methanogens with concurrent improvement in constipation symptoms [76-78].”
From Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota (2021) · cites this paper as [76]
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 2×
“Consecutive patients (18–65 years of age) who fulfilled the Rome II criteria for C-IBS [2] were recruited.”
BackgroundMethodThe burden of selected digestive diseases in the United States
Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32978 · Cited by 1,512 · cited 1×
“Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder accounting for significant health care and economic costs in gastroenterology [1].”
BackgroundRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationPimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00574.2004 · Cited by 508 · cited 2×
“More importantly, a cause-and-effect relationship between methane and transit was suggested based on animal studies [12].”
BackgroundSelf-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499 · cited 1×
“Another hypothesis finds that small intestinal bacterial overgrowth (SIBO) contributes to the pathogenesis of IBS based upon breath testing [5], small bowel culture [6, 7], small bowel qPCR [8] and response to antibiotics [9] in non-C-IBS subjects.”
BackgroundTHABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466 · cited 1×
“Based on two meta-analyses, IBS develops in approximately 10 % of subjects after acute gastroenteritis [3, 4].”
BackgroundPostinfectious Irritable Bowel Syndrome-A Meta-Analysis
Halvorson, H. A., Schlett, C. D., & Riddle, M. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00654.x · Cited by 352
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283
Attaluri, A., Jackson, M., Valestin, J., & Rao, S. S. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.655 · Cited by 261 · cited 3×
“Breath test studies suggest that methane production is associated with constipation and C-IBS [10, 11].”
BackgroundSelf-citationThe Degree of Breath Methane Production in IBS Correlates With the Severity of Constipation
Chatterjee, S., Park, S., Low, K., Kong, Y., & Pimentel, M. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01072.x · Cited by 232 · cited 3×
“First and foremost, methane appears to be a marker for C-IBS [13].”
BackgroundSelf-citation
Cited by
Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.46 · Cited by 852
“…the severity of constipation directly correlated with the methane level ( 50 ) and the choice of antibiotics for the treatment of SIBO diff ers between these two groups as the predominant methanogen in the human gut, Methanobrevibacter smithii , is resistant to many antibiotics ( 22,38,54 ).”
BackgroundSelf-citationAntibiotics as deep modulators of gut microbiota: between good and evil
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016) · Gut · doi:10.1136/gutjnl-2016-312297 · Cited by 625
Global burden of irritable bowel syndrome: trends, predictions and risk factors
Black, C. J., & Ford, A. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0286-8 · Cited by 610
A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies
Rodiño-Janeiro, B. K., Vicario, M., Alonso-Cotoner, C., Pascua-García, R., & Santos, J. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0673-5 · Cited by 214
Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles
Sinha, T., Vich Vila, A., Garmaeva, S., Jankipersadsing, S. A., Imhann, F., Collij, V., Bonder, M. J., Jiang, X., Gurry, T., Alm, E. J., et al. (2019) · Gut Microbes · doi:10.1080/19490976.2018.1528822 · Cited by 208
“Antibiotic treatment has been associated with both increased risk for IBS2 and therapeutic effects in IBS, both of which are more common in women.7,39 We therefore sought to test the potential relevance of the observed sex-specific resistome differences to (self-reported) IBS.”
BackgroundMethodInfluentialBlack, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome—An Update
Takakura, W., & Pimentel, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00664 · Cited by 148
“Of note, while neomycin and rifaximin can each reduce constipation in IBS-C, using a combination of both appears to be most effective (84).”
BackgroundSelf-citationMicrobiome and Its Role in Irritable Bowel Syndrome
Pimentel, M., & Lembo, A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06109-5 · Cited by 167
Self-citationHow to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach
Rezaie, A., Pimentel, M., & Rao, S. S. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0482-9 · Cited by 161
Self-citationDysbiosis in gastrointestinal disorders
Chang, C., & Lin, H. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.02.001 · Cited by 158
Self-citationMearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4389/2016 · Cited by 139
Management Options for Irritable Bowel Syndrome
Camilleri, M. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.032 · Cited by 109
“The acceleration of colonic transit would seem deleterious for patients with IBS-D; conversely, it may explain the reported improvement in IBS-C (bloating, constipation, and straining) with combined neomycin plus rifaximin compared with neomycin with placebo.(128) Importantly, there is no evidence of adverse effects w…”
Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota
Bloor, S. R., Schutte, R., & Hobson, A. R. (2021) · Microbiology Research · doi:10.3390/microbiolres12020033 · Cited by 117
Shah, A., Morrison, M., Burger, D. C., Martin, N., Rich, J., Jones, M., Koloski, N. A., Walker, M. M., Talley, N. J., & Holtmann, G. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15133 · Cited by 122
Wang, L., Yao, Y., He, R., Meng, Y., Li, N., Zhang, D., Xu, J., Ouyang, C., Cui, J., Bian, J., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.014 · Cited by 108
Small Intestinal Bacterial Overgrowth
Adike, A., & DiBaise, J. K. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.09.008 · Cited by 125
Self-citationGhoshal, U. C., Sachdeva, S., Ghoshal, U., Misra, A., Puri, A. S., Pratap, N., Shah, A., Rahman, M. M., Gwee, K. A., Tan, V. P. Y., et al. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-022-01292-x · Cited by 109
Acosta, A., Camilleri, M., Shin, A., Nord, S. L., O'Neill, J., Gray, A. V., Lueke, A. J., Donato, L. J., Burton, D. D., Szarka, L. A., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.32 · Cited by 88
“3 at 24 h (as 2.3 is the median of values in our laboratory for healthy adults, as well as being greater than the upper range of the 99% confidence interval for patients with IBS-C (median 1.95, 99% confidence interval 1.71–2.24))29 to exclude IBS-C.”
BackgroundInfluentialBarlow, J. T., Leite, G., Romano, A. E., Sedighi, R., Chang, C. Y.-Y., Celly, S., Rezaie, A. R., Mathur, R., Pimentel, M., & Ismagilov, R. F. (2021) · Microbiome · doi:10.1186/s40168-021-01162-2 · Cited by 99
“However, reoccurrence of symptoms after antibiotics is common and adherence to strict diets is often difficult for patients [17].”
BackgroundSelf-citationPimentel, M. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13437 · Cited by 75
Self-citationItalian guidelines for the management of irritable bowel syndrome
Barbara, G., Cremon, C., Bellini, M., Corsetti, M., Nardo, G. D., Falangone, F., Fuccio, L., Galeazzi, F., Iovino, P., Sarnelli, G., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.11.015 · Cited by 88
“with neomycin alone, and the effect as accompanied by a reduction in breath methane [176].”
BackgroundChen, Q., Ren, Y., Lu, J., Bartlett, M., Chen, L., Zhang, Y., Guo, X., & Liu, C. (2017) · Nutrients · doi:10.3390/nu9121341 · Cited by 84
Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis
Ghosh, G., & Jesudian, A. B. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.08.006 · Cited by 83
“However, there are conflicting data regarding the benefit of adding neomycin to rifaximin for SIBO eradication in methane producers.(65) Unfortunately, treatment with antibiotics may only provide a temporary response if the underlying risk factors for SIBO are not corrected as treatment with antibiotics is associated”
BackgroundBiomarkers of Irritable Bowel Syndrome
Kim, J. H., Lin, E. A., & Pimentel, M. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16135 · Cited by 77
Self-citationAchufusi, T. G., Sharma, A., Zamora, E. A., & Manocha, D. (2020) · Cureus · doi:10.7759/cureus.8860 · Cited by 79
“Contrary to prior studies, where methane level measurement did not increase the yield of hydrogen breath testing, recent data suggest checking methane levels does increase the diagnostic yield of hydrogen breath testing and should be used for diagnostic purposes [3, 16].”
ResultChey, W. D., Shah, E. D., & DuPont, H. L. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819897531 · Cited by 62
Ghoshal, U. C., Srivastava, D., & Misra, A. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0901-6 · Cited by 56
Revisiting the intestinal microbiome and its role in Diarrhea and constipation
Iancu, M. A., Profir, M., Roşu, O. A., Ionescu, R. F., Cretoiu, S. M., & Gaspar, B. S. (2023) · Microorganisms · doi:10.3390/microorganisms11092177 · Cited by 53
Research progress of colon-targeted oral hydrogel system based on natural polysaccharides
Wang, D., Wang, W., Wang, P., Wang, C., Niu, J., Liu, Y., & Chen, Y. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123222 · Cited by 53
Pharmacotherapy for Irritable Bowel Syndrome
Camilleri, M., & Ford, A. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110101 · Cited by 46
“Some patients with IBS may have underlying small intestinal bacterial overgrowth (SIBO), detected on hydrogen breath testing, and this can be reversed with non-absorbable antibiotics such as rifaximin [76].”
BackgroundGut Microbiota-Based Therapies for Irritable Bowel Syndrome
Stern, E., & Brenner, D. M. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2018.2 · Cited by 56
“In this trial, 32 patients were randomly assigned to 14 days of treatment with either neomycin 500 mg twice daily plus placebo 3 times daily or neomycin 500 mg twice daily plus rifaximin 550 mg 3 times daily.(61) Patients in the neomycin plus rifaximin group noted significant improvements compared with the neomycin pl…”
MethodResultInfluentialStrifler, G., Tuboly, E., Szél, E., Kaszonyi, E., Cao, C., Kaszaki, J., Mészáros, A., Boros, M., & Hartmann, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146363 · Cited by 47
Foxx–Orenstein, A. E. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16633050 · Cited by 48
Role of Inflammation in Pathophysiology of Colonic Disease: An Update
Nasef, N. A., & Mehta, S. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134748 · Cited by 49
Irritable bowel syndrome: diagnosis and management
Masuy, I., Pannemans, J., & Tack, J. F. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02640-0 · Cited by 49
Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome
Singh, P., & Lembo, A. J. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.03.003 · Cited by 42
Takakura, W., Pimentel, M., Rao, S., Villanueva-Millan, M. J., Chang, C., Morales, W., Sanchez, M., Torosyan, J., Rashid, M., Hosseini, A., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001607 · Cited by 42
“Reduction of CH4 levels in patients with IMO correlates with improvement of symptoms (9).”
BackgroundInfluentialSelf-citationGhoshal, U. C., Sachdeva, S., Pratap, N., Karyampudi, A., Mustafa, U., Abraham, P., Bhatt, C. B., Chakravartty, K., Chaudhuri, S., Goyal, O., et al. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-022-01333-5 · Cited by 53
“Two other studies from the USA, one prospective and the other retrospective, also supported the findings of this study [23, 24].”
ResultGut microbiota and irritable bowel syndrome: status and prospect
Cheng, X., Ren, C., Mei, X., Jiang, Y., & Zhou, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1429133 · Cited by 52
Gut Microbiota Manipulation in Irritable Bowel Syndrome
Mazzawi, T. R. E. (2022) · Microorganisms · doi:10.3390/microorganisms10071332 · Cited by 46
Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
Li, J., Zhu, W., Liu, W., Wu, Y., & Wu, B. (2016) · Medicine · doi:10.1097/md.0000000000002534 · Cited by 35
Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches
Camilleri, M., & Ford, A. C. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_102 · Cited by 41
Ghoshal, U. C. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15032 · Cited by 42
Phan, J., Nair, D., Jain, S., Montagne, T., Flores, D. V., Nguyen, A., Dietsche, S., Gombar, S., & Cotter, P. (2021) · mSystems · doi:10.1128/msystems.01215-21 · Cited by 33
Antibiotics and Probiotics for Irritable Bowel Syndrome
Goodoory, V. C., & Ford, A. C. (2023) · Drugs · doi:10.1007/s40265-023-01871-y · Cited by 34
“Although a clear causality between these alterations in the microbiota and predominant stool pattern has yet to be demonstrated, an RCT recruiting 31 individuals with IBS-C with a positive methane breath test demonstrated that those with lower levels of methane after antibiotic treatment had a significantly greater im…”
BackgroundBreath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?
Pimentel, M. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.30 · Cited by 31
Self-citationMousavi, T., Nikfar, S., & Abdollahi, M. R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1767067 · Cited by 32
“Co-administration of neomycin and rifaximin in breath methane positive IBS-C patients, decreased constipation severity, straining, abdominal bloating and stool consistency more than neomycin itself, whilst abdominal pain didn’t differ markedly [80].”
BackgroundLaxative effect and mechanism of Tiantian Capsule on loperamide-induced constipation in rats
Li, T., Hu, M., Jiang, C., Zhang, D., Gao, M. Q., Xia, J., Miao, M., Shi, G., Li, H., Zhang, J., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113411 · Cited by 31
Mehravar, S., Takakura, W., Wang, J., Pimentel, M., Nasser, J., & Rezaie, A. R. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.020 · Cited by 44
Self-citationSmall Intestinal Bacterial Overgrowth
Maneerattanaporn, M., & Chey, W. D. (2010) · Wiley eBooks · doi:10.1002/9781444328417.ch35 · Cited by 28
Redondo‐Cuevas, L., Belloch, L., Martín-Carbonell, V., Nicolás, A., Alexandra, I., Artero, L. S., Ynfante, M., Colmenares, M., Mora, M., Liebana, A. R., et al. (2024) · Nutrients · doi:10.3390/nu16071083 · Cited by 36
“This could be due to the addition of neomycin to rifaximin in the treatment of CH 4 -SIBO [36].”
BackgroundGut microbiota and irritable bowel syndrome
Zhao, Y., & Zou, D. (2023) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13204 · Cited by 33
“tion, it has been proposed that rifaximin may exert therapeutic effects on IBS-C, but higher-quality, prospective researches are necessary to verify its clinical application.(78,82) ZHAO and ZOU 315”
BackgroundDale, H. F., & Lied, G. A. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2002-57 · Cited by 32
“Although rifaximin is not indicated in IBS-C, a small double-blind trial has suggested that rifaximin may improve symptoms also in patients with constipation [61].”
BackgroundRifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation
Ponziani, F. R., Pecere, S., Lopetuso, L. R., Scaldaferri, F., Cammarota, G., & Gasbarrini, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1186639 · Cited by 26
“Finally, two studies with a small sample size explored the effects of rifaximin on functional symptoms in patients with CIBS and increased colonic fermentation, demonstrated by methane excretion at lactulose breath test.[50,52] Alone or associated with neomycin, rifaximin improved symptoms severity, especially constip…”
BackgroundBile acid–gut microbiota crosstalk in irritable bowel syndrome
Gu, Y., Li, L., Yang, M., Liu, T., Song, X., Qin, X., Xu, X. J., Liu, J., Wang, B., & Cao, H. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2058353 · Cited by 30
“A number of clinical trials applying rifaximin in different IBS subsets have been carried out, and positive results have been obtained (Sharara et al. 2006; Pimentel et al. 2011; Pimentel et al. 2014; Schoenfeld et al. 2014).”
BackgroundSmall Intestinal Bacterial Overgrowth
Ginnebaugh, B. D., Chey, W. D., & Saad, R. J. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2020.04.010 · Cited by 32
Waqar, S. H. B., & Rehan, A. (2019) · Cureus · doi:10.7759/cureus.4764 · Cited by 28
Outcome of hospital outpatient treatment of functional gastrointestinal disorders
Basnayake, C., Kamm, M. A., Salzberg, M. R., Stanley, A., Khera, A. J., Burrell, K., Wilson-O'Brien, A. L., Hebbard, G., & Thompson, A. J. V. (2018) · Internal Medicine Journal · doi:10.1111/imj.14067 · Cited by 23
Yokoyama, K., Sakamaki, A., Takahashi, K., Naruse, T., Sato, C., Kawata, Y., Tominaga, K., Abé, H., Sato, H., Tsuchiya, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264459 · Cited by 26
Abdelghafar, Y. A., AbdelQadir, Y. H., Motawea, K. R., Nasr, S. A., Omran, H. A. M., Belal, M. M., Elhashash, M. M., AbdelAzim, A. A., & Shah, J. (2022) · Health Science Reports · doi:10.1002/hsr2.814 · Cited by 25
“Using antibiotics that are poorly absorbed from GIT like rifaximin and neomycin is now used more widely, but its main flaw is the lack of specificity as it may affect the harmless flora as well.(37) Now, precision antimicrobial peptides called selectively targeted antimicrobial peptides were developed to target certai…”
BackgroundIrritable bowel syndrome – controversies in diagnosis and management
Duncanson, K., Tikhe, D., Williams, G. M., & Talley, N. J. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2223975 · Cited by 25
“whether small intestinal bacterial overgrowth (SIBO) should be routinely screened for and treated in IBS remains poorly evidence based [57,109].”
BackgroundProfile of rifaximin and its potential in the treatment of irritable bowel syndrome
Schey, R., Iorio, N., & Malik, Z. A. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s67231 · Cited by 26
Update on Pharmacotherapy for Irritable Bowel Syndrome
Munjal, A., Dedania, B. K., & Cash, B. D. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0692-7 · Cited by 22
Rangan, V., Nee, J. W., & Lembo, A. J. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.02.031 · Cited by 21
Dittmann, M. T., Hammond, K. J., Kirton, P., Humphries, D. J., Crompton, L. A., Ortmann, S., Misselbrook, T. H., Südekum, K., Schwarm, A., Kreuzer, M., et al. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516002701 · Cited by 25
“target methanogens led to a reduction in constipation-related symptoms((24,72)).”
Shin, A., Xing, Y., Waseem, M. R., Siwiec, R. M., James-Stevenson, T. N., Rogers, N. A., Bohm, M. E., Wo, J. M., Lockett, C. J., Gupta, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19363-2 · Cited by 30
“Our findings may further explain the higher prevalence of mixed-and diarrhea-predominant symptoms in post-infection IBS 43,44 as well as the limited evidence for efficacy of antimicrobial treatments such as rifaximin in IBS-C 45 relative to IBS-D 46,47 .”
Small Intestinal Bacterial Overgrowth in Children
Fabregat, M. I. P., Gardner, R. M., Hassan, M., Kapphahn, K., & Yeh, A. M. (2022) · JPGN Reports · doi:10.1097/pg9.0000000000000185 · Cited by 16
“In adults, studies report that rifaximin and neomycin are effective for IBS, especially when combined (8), but insufficient evidence exists for children.”
Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome
Liu, A., Gao, W., Zhu, Y., Hou, X., & Chu, H. (2022) · Toxins · doi:10.3390/toxins14090596 · Cited by 19
“Furthermore, the test has been recommended for patients with clinical constipation or slow gastrointestinal transmission [187] and to assist in the identification of IBS-C [9,183,188].”
BackgroundInfluentialSingh, P., Duehren, S., Katon, J. M., Rangan, V., Ballou, S., Patel, R., Iturrino, J., Lembo, A. J., & Nee, J. W. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001239 · Cited by 15
Can Lactose Intolerance Be a Cause of Constipation? A Narrative Review
Leszkowicz, J., Plata‐Nazar, K., & Szlagatys‐Sidorkiewicz, A. (2022) · Nutrients · doi:10.3390/nu14091785 · Cited by 20
Mearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2017) · Atención Primaria · doi:10.1016/j.aprim.2017.01.003 · Cited by 20
Lim, J. E., & Rezaie, A. R. (2023) · PubMed Central · Cited by 23
Mareș, C. R., Săsăran, M. O., & Mărginean, C. O. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1431660 · Cited by 15
Takakura, W., Oh, S. J., Singer-Englar, T., Mirocha, J., Leite, G., Fridman, A., Pimentel, M., Mathur, R., Pichetshote, N., & Rezaie, A. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-57662-y · Cited by 15
Self-citationRamos, G. P., & Camilleri, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07700-8 · Cited by 15
“Indeed, some studies also showed benefit of rifaximin in the treatment of patients with IBS-constipation [54, 55].”
BackgroundGhodratı, A. D., & Çomoğlu, T. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400356 · Cited by 14
Baker, J. R., Chey, W. D., Watts, L. S., Armstrong, M., Collins, K., Lee, A. A., Dupati, A., Menees, S. B., Saad, R. J., Harer, K. N., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001110 · Cited by 13
Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome
Algera, J. P., Törnblom, H., & Simrén, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102284 · Cited by 10
New and Investigational Agents for Irritable Bowel Syndrome
Wadhwa, A., Camilleri, M., & Grover, M. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0473-x · Cited by 12
Myths and Misconceptions About Constipation: A New View for the 2020s
Staller, K., & Cash, B. D. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000947 · Cited by 10
Teigen, L. M., Mathai, P. P., Matson, M., Lopez, S., Kozysa, D., Kabage, A. J., Hamilton, M. J., Vaughn, B. P., Sadowsky, M. J., & Khoruts, A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06721-5 · Cited by 11
Oh, C. K., Chung, H. H., Kim, Y. J., & Kim, J. B. (2025) · Nutrients · doi:10.3390/nu17050763 · Cited by 11
“On the basis of previous studies, we estimated the rifaximin response rate to be up to 30–40% [13,14,23,24].”
Brown, K., Scott-Hoy, B., & Jennings, L. W. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i3.463 · Cited by 8
Gas-tly Interpretations: A Case-Based Approach to the Nuances of SIBO Breath Testing
Damianos, J., Matar, A., & Halawi, H. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00977-5 · Cited by 10
Recent Updates on the Treatment of Constipation
Ryu, H. S., & Choi, S. C. (2015) · Intestinal Research · doi:10.5217/ir.2015.13.4.297 · Cited by 11
“org to be more effective than neomycin alone.(52) However, the criteria for the breath test have not been properly established, and it is therefore difficult to conclude that there is an association between methane production and constipation.”
BackgroundIribarren, C., Maasfeh, L., Öhman, L., & Simrén, M. (2022) · Gut Microbiome · doi:10.1017/gmb.2022.6 · Cited by 9
“Besides, it can normalise breath test results (Soldi et al., 2015; Yang et al., 2008), especially in combination with neomycin in patients with abnormal levels of methane (Low et al., 2010; Pimentel et al., 2014), potentially reflecting changes in microbial fermentation (Sharara et al., 2006).”
BackgroundInfluentialBrown, K., Scott-Hoy, B., & Jennings, L. W. (2015) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2015.04.560 · Cited by 8
Clinical Conditions Associated With Bacterial Overgrowth
Shah, A., & Holtmann, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00006-4 · Cited by 8
Zhang, Q., Li, H., Chen, C., Li, M., Song, J., Pan, S., Shen, B., & Huang, Y. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251399033 · Cited by 8
Unravelling the controversy with small intestinal bacterial overgrowth
Shah, A., Ghoshal, U. C., & Holtmann, G. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000928 · Cited by 8
Algorithms or biomarkers in patients with lower DGBI ?
Camilleri, M., & Yang, D. Y. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14856 · Cited by 7
Yakovenko, E. P., Строкова, Т. В., Ivanov, A. N., Iakovenko, A. V., Iz, G., & Алдиярова, М. А. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.02.201368 · Cited by 7
Stemboroski, L. N., & Schey, R. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2020.05.001 · Cited by 6
Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis
Damianos, J., Wang, X. J., & Camilleri, M. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00295-x · Cited by 8
Munjal, A., Dedania, B. K., & Cash, B. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691524 · Cited by 6
Rosenthal, B. E., Zoll, B. E., Ryan, H. N., Toto, E. C., Reynolds, J. C., & Ahuja, N. K. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.07.001 · Cited by 5
Algo-dysfunctional syndromes: a critical digest of the recent literature.
Talotta, R., Atzeni, F., Bazzichi, L. M., Giacomelli, C., Franco, M. D., Salaffi, F., & Sarzi‐Puttini, P. (2015) · PubMed · Cited by 6
Shah, Q., & Soldera, J. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i1.107169 · Cited by 5
Sakamaki, A., Yokoyama, K., Yamazaki, H., Wakabayashi, T., 五十嵐, 崇., Kojima, Y., Tominaga, K., Abé, H., Tsuchiya, A., Kamimura, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051491 · Cited by 8
“Methanobrevibacter smithii , the predominant methanogenic bacterium in the human gut, is resistant to many antibiotics; therefore, antibiotics are not considered effective for the treatment of M-SIBO [37–39].”
Bloating and Abdominal Distension: Exploring Hidden Depths and Insights
Pichetshote, N., & Rezaie, A. R. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00288-w · Cited by 5
Metadata
- Authors
- Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Mayo Clinic (US)
- Augusta University (US)
- Corresponding author
- Pimentel, Mark
- Venue
- Digestive Diseases and Sciences
- Published
- 2014-05-01
- Volume
- 59
- Issue
- 6
- Pages
- 1278-1285
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2094665977
- Cited by
- 143
- References
- 17
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 14 · 2023: 11 · 2022: 16 · 2021: 9 · 2020: 20 · 2019: 9 · 2018: 8 · 2017: 9 · 2016: 17 · 2015: 7 · 2014: 2
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- irritable bowel syndrome with constipation, rifaximin, neomycin, breath methane, antibiotic therapy, constipation severity, bloating, straining, abdominal pain
- MeSH terms
- Rifaximin, Adult, Anti-Infective Agents, Breath Tests, Constipation, Female, Gastrointestinal Agents, Humans, Male, Methane, Middle Aged, Neomycin, Rifamycins, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.